Regulatory Update: Three FDA Approvals and Two Priority Reviews

FDA focuses on reorganization, Welireg Priority Review, New Ozempic approval is a firstПодробнее

FDA Approvals, Breakthrough Designations, Priority Reviews, and MoreПодробнее

Deep dive into FDA’s expedited programs for drug developmentПодробнее

FDA Approval in CRC, Priority Review in HCC, Encouraging Data in Myeloma Trial, and MoreПодробнее

Expedited Programs for Drug ApprovalsПодробнее

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and MoreПодробнее

FDA Approval in NSCLC, Priority Review Designation in SCLC, CRL to Biosimilar, and MoreПодробнее

Cynthia Kelly Discusses Regulatory Mechanisms to Facilitate Medical CountermeasuresПодробнее

FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the YearПодробнее

FDA Approval for CLL, ODAC Vote in Lung Cancer, European Regulatory Advances, and MoreПодробнее

pathways to U.S. FDA drug approvalПодробнее

FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and MoreПодробнее

Working with Regulators: A focus on the FDA: MainПодробнее

Orange Book Exclusivity: Part II - Pediatric, Orphan, and GAINПодробнее

FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and MoreПодробнее

FDA Approves TAS-102, Nivolumab Breakthrough in RCC, Two Priority Reviews, and MoreПодробнее

Advancing Generic Drug Development: Translating Science to Approval, Day Two Closing RemarksПодробнее

Four FDA Approvals, Two Priority Reviews, and SABCS HighlightsПодробнее

Common CMC (Quality) Issues and How to Avoid Them Part II (13of16) Generic Drugs Forum 2020Подробнее